{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Topham JT"],"pubmed_abstract":["Over a decade of sequencing-based genomics research has unveiled a diverse somatic mutation landscape across patients with pancreatic ductal adenocarcinoma (PDAC), and the identification of druggable mutations has aligned with the development of novel targeted therapeutics. However, despite these advances, direct translation of years of PDAC genomics research into the clinical care of patients remains a critical and unmet need. Technologies that enabled the initial mapping of the PDAC mutation landscape, namely whole-genome and transcriptome sequencing, remain overly expensive in terms of both time and financial resources. Consequentially, dependence on these technologies to identify the relatively small subset of patients with actionable PDAC alterations has greatly impeded enrollment for"],"journal":["Therapeutic advances in medical oncology"],"pagination":["17588359231157651"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989430"],"repository":["biostudies-literature"],"pubmed_title":["Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma."],"pmcid":["PMC9989430"],"pubmed_authors":["Renouf DJ","Schaeffer DF","Topham JT"],"additional_accession":[]},"is_claimable":false,"name":"Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma.","description":"Over a decade of sequencing-based genomics research has unveiled a diverse somatic mutation landscape across patients with pancreatic ductal adenocarcinoma (PDAC), and the identification of druggable mutations has aligned with the development of novel targeted therapeutics. However, despite these advances, direct translation of years of PDAC genomics research into the clinical care of patients remains a critical and unmet need. Technologies that enabled the initial mapping of the PDAC mutation landscape, namely whole-genome and transcriptome sequencing, remain overly expensive in terms of both time and financial resources. Consequentially, dependence on these technologies to identify the relatively small subset of patients with actionable PDAC alterations has greatly impeded enrollment for","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-05T14:16:45.143Z","creation":"2025-02-19T04:43:47.039Z"},"accession":"S-EPMC9989430","cross_references":{"pubmed":["36895849"],"doi":["10.1177/17588359231157651"]}}